← All trials
NCT07114874
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 11, 2025
- Primary completion
- Dec 31, 2031
- Completion date
- Dec 31, 2031
- First posted
- Aug 11, 2025
- Last posted
- Oct 22, 2025
- Enrollment
- 800
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Neurocrine BiosciencesLead sponsor
- Neurocrine BiosciencesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.